NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BIIB shares have decreased by 6.2% and is now trading at $276.08.
View which stocks have been most impacted by Coronavirus.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 17 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings data on Wednesday, July, 22nd. The biotechnology company reported $10.26 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $8.03 by $2.23. The biotechnology company had revenue of $3.68 billion for the quarter, compared to the consensus estimate of $3.44 billion. Biogen had a return on equity of 50.10% and a net margin of 40.91%. During the same quarter in the prior year, the business earned $9.15 earnings per share.
View Biogen's earnings history.

Biogen declared that its Board of Directors has approved a stock buyback program on Monday, December 23rd 2019, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board believes its stock is undervalued.

Biogen issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided EPS guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

31 Wall Street analysts have issued 12 month target prices for Biogen's stock. Their forecasts range from $228.00 to $410.00. On average, they anticipate Biogen's share price to reach $307.79 in the next twelve months. This suggests a possible upside of 11.5% from the stock's current price.
View analysts' price targets for Biogen.

News stories about BIIB stock have been trending neutral on Wednesday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Biogen earned a media sentiment score of 0.4 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future.
View the latest news about Biogen.

Biogen saw a drop in short interest in the month of July. As of July 15th, there was short interest totaling 2,780,000 shares, a drop of 14.7% from the June 30th total of 3,260,000 shares. Based on an average daily volume of 1,610,000 shares, the days-to-cover ratio is presently 1.7 days. Currently, 1.8% of the company's stock are short sold.
View Biogen's Current Options Chain.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by many different retail and institutional investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.48%), Robeco Institutional Asset Management B.V. (0.25%), First Trust Advisors LP (0.24%), Candriam Luxembourg S.C.A. (0.21%), Railway Pension Investments Ltd (0.20%) and Assenagon Asset Management S.A. (0.20%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Ziegler Capital Management LLC, Candriam Luxembourg S.C.A., Pzena Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., New York State Teachers Retirement System, Mn Services Vermogensbeheer B.V., and Oregon Public Employees Retirement Fund. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., PGGM Investments, Robeco Institutional Asset Management B.V., SG Americas Securities LLC, MERIAN GLOBAL INVESTORS UK Ltd, State of Michigan Retirement System, QCI Asset Management Inc. NY, and Railway Pension Investments Ltd. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $276.08.

Biogen has a market capitalization of $43.71 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]